Show simple item record

dc.contributor.authorGuzman-Villanueva, Diana
dc.contributor.authorMigrino, Raymond Q.
dc.contributor.authorTruran, Seth
dc.contributor.authorKaramanova, Nina
dc.contributor.authorFranco, Daniel A.
dc.contributor.authorBurciu, Camelia
dc.contributor.authorSenapati, Subhadip
dc.contributor.authorNedelkov, Dobrin
dc.contributor.authorHari, Parameswaran
dc.contributor.authorWeissig, Volkmar
dc.date.accessioned2018-05-24T21:38:16Z
dc.date.available2018-05-24T21:38:16Z
dc.date.issued2018-02
dc.identifier.citationDiana Guzman-Villanueva, Raymond Q. Migrino, Seth Truran, Nina Karamanova, Daniel A. Franco, Camelia Burciu, Subhadip Senapati, Dobrin Nedelkov, Parameswaran Hari & Volkmar Weissig (2017): PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction, Journal of Liposome Research, DOI: 10.1080/08982104.2016.1274756en_US
dc.identifier.issn0898-2104
dc.identifier.issn1532-2394
dc.identifier.pmid28103719
dc.identifier.doi10.1080/08982104.2016.1274756
dc.identifier.urihttp://hdl.handle.net/10150/627800
dc.description.abstractLight chain (AL) amyloidosis is a disease associated with significant morbidity and mortality arising from multi-organ injury induced by amyloidogenic light chain proteins (LC). There is no available treatment to reverse the toxicity of LC. We previously showed that chaperone glycoprotein clusterin (CLU) and nanoliposomes (NL), separately, restore human microvascular endothelial function impaired by LC. In this work, we aim to prepare PEGylated-nanoliposomal clusterin (NL-CLU) formulations that could allow combined benefit against LC while potentially enabling efficient delivery to microvascular tissue, and test efficacy on human arteriole endothelial function. NL-CLU was prepared by a conjugation reaction between the carboxylated surface of NL and the primary amines of the CLU protein. NL were made of phosphatidylcholine (PC), cholesterol (Chol) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000] (DSPE-PEG 2000 carboxylic acid) at 70:25:5mol%. The protective effect of NL-CLU was tested by measuring the dilation response to acetylcholine and papaverine in human adipose arterioles exposed to LC. LC treatment significantly reduced the dilation response to acetylcholine and papaverine; co-treatment of LC with PEGylated-nanoliposomal CLU or free CLU restored the dilator response. NL-CLU is a feasible and promising approach to reverse LC-induced endothelial damage.en_US
dc.description.sponsorshipCollege of Pharmacy-Glendale, Midwestern Universityen_US
dc.language.isoenen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.relation.urlhttps://www.tandfonline.com/doi/full/10.1080/08982104.2016.1274756en_US
dc.rights© 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Groupen_US
dc.subjectAmyloidosisen_US
dc.subjectclusterinen_US
dc.subjectlight chainen_US
dc.subjectliposomesen_US
dc.subjectPEGylationen_US
dc.titlePEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunctionen_US
dc.typeArticleen_US
dc.contributor.departmentUniv Arizona, Coll Meden_US
dc.identifier.journalJOURNAL OF LIPOSOME RESEARCHen_US
dc.description.noteOpen access article.en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal published versionen_US
dc.source.journaltitleJournal of Liposome Research
dc.source.volume28
dc.source.issue2
dc.source.beginpage97
dc.source.endpage105
refterms.dateFOA2018-05-24T21:38:16Z


Files in this item

Thumbnail
Name:
guzman_villanueva_pegylated_na ...
Size:
725.1Kb
Format:
PDF
Description:
Final Published version

This item appears in the following Collection(s)

Show simple item record